论文部分内容阅读
目的探讨硝苯地平联合厄贝沙坦治疗社区2型糖尿病合并高血压患者的临床疗效。方法选取上海市浦东新区金杨社区卫生服务中心2011年1月—2015年1月收治的2型糖尿病合并高血压患者320例,随机分为对照组和治疗组,各160例。患者入院后均给予常规对症治疗,对照组患者给予硝苯地平缓释片治疗;治疗组患者在对照组基础上联合厄贝沙坦分散片治疗,均持续治疗6个月。比较两组患者的临床疗效、收缩压、舒张压及不良反应发生情况。结果治疗组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者收缩压、舒张压比较,差异无统计学意义(P>0.05);治疗后,治疗组患者收缩压、舒张压低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论硝苯地平联合厄贝沙坦治疗社区2型糖尿病合并高血压患者的临床疗效明显,可有效降低血压,且安全可靠。
Objective To investigate the clinical efficacy of nifedipine combined with irbesartan in the treatment of community type 2 diabetes mellitus patients with hypertension. Methods A total of 320 type 2 diabetic patients with hypertension were enrolled in Jinyang Community Health Service Center, Pudong New District, Shanghai from January 2011 to January 2015, and randomly divided into control group and treatment group with 160 cases each. All patients were given conventional symptomatic treatment after admission, and patients in the control group were given nifedipine sustained-release tablets. Patients in the treatment group were treated with irbesartan dispersible tablets on the basis of the control group, and were treated for 6 months. The clinical efficacy, systolic blood pressure, diastolic blood pressure and adverse reactions of the two groups were compared. Results The clinical efficacy of the treatment group was better than that of the control group (P <0.05). Before treatment, there was no significant difference in systolic pressure and diastolic pressure between the two groups (P> 0.05). After treatment, the systolic pressure and diastolic pressure in the treatment group were lower than those in the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Nifedipine combined with irbesartan in the treatment of community-type 2 diabetes mellitus patients with hypertension has obvious curative effect, which can effectively reduce blood pressure and is safe and reliable.